Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects must give a written, signed and dated informed consent
Chronic plaque-type psoriasis present for at least 6 months before randomization
Moderate to severe plaque psoriasis as defined at randomization by:
Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
1,114 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal